Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges.

Lung cancer is the commonest cause of cancer death in the world and carries a poor prognosis for most patients. While precision targeting of mutated proteins has given some successes for never- and light-smoking patients, there are no proven targeted therapies for the majority of smokers with the disease. Despite sequencing hundreds of lung cancers, known driver mutations are lacking for a majority of tumors. Distinguishing driver mutations from inconsequential passenger mutations in a given lung tumor is extremely challenging due to the high mutational burden of smoking-related cancers. Here we discuss the methods employed to identify driver mutations from these large datasets. We examine different approaches based on bioinformatics, in silico structural modeling and biological dependency screens and discuss the limitations of these approaches.

[1]  J. Mesirov,et al.  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.

[2]  I. Herskowitz.  Functional inactivation of genes by dominant negative mutations , 1987, Nature.

[3]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[4]  P. Hanawalt,et al.  Transcription-coupled DNA repair: two decades of progress and surprises , 2008, Nature Reviews Molecular Cell Biology.

[5]  Jessica Zucman-Rossi,et al.  p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. , 2010, Lung cancer.

[6]  C. Echeverri,et al.  Oncology studies using siRNA libraries: the dawn of RNAi-based genomics , 2004, Oncogene.

[7]  Ying-Ting Lin,et al.  Functional characterization of a novel missense mutation, His147Arg, in A1 domain of FV protein causing type II deficiency. , 2014, Thrombosis research.

[8]  Jill P. Mesirov,et al.  β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2012, Cell.

[9]  B. Ma,et al.  R102Q mutation shifts the salt-bridge network and reduces the structural flexibility of human neuronal calcium sensor-1 protein. , 2014, The journal of physical chemistry. B.

[10]  K. Gold.  ROS1--targeting the one percent in lung cancer. , 2014, The New England journal of medicine.

[11]  R. Purohit,et al.  Relationship between a point mutation S97C in CK1δ protein and its affect on ATP-binding affinity , 2014, Journal of biomolecular structure & dynamics.

[12]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[13]  W. Hahn,et al.  ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.

[14]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[15]  Francesco Luigi Gervasio,et al.  Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase , 2013, Proceedings of the National Academy of Sciences.

[16]  J. Stamatoyannopoulos,et al.  Human mutation rate associated with DNA replication timing , 2009, Nature Genetics.

[17]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[18]  S. Fesik,et al.  Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. , 2007, Cancer research.

[19]  Bohdan Waszkowycz,et al.  Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer , 2013, Proceedings of the National Academy of Sciences.

[20]  S. Hecht,et al.  Tobacco smoke carcinogens and lung cancer. , 1999, Journal of the National Cancer Institute.

[21]  Yi-long Wu,et al.  Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[23]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[24]  Ronglai Shen,et al.  Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers , 2012, Clinical Cancer Research.

[25]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[26]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[27]  L. Trusolino,et al.  Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils , 2011, EMBO molecular medicine.

[28]  T. Hunter,et al.  Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor-suppressing kinase. , 2011, Cancer research.

[29]  D. Haber,et al.  Cancer: Drivers and passengers , 2007, Nature.

[30]  Gary D Bader,et al.  Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers , 2013 .

[31]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[32]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[33]  J. Brenton,et al.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. , 2007, Cancer cell.

[34]  R. Gibbs,et al.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.

[35]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[37]  M. Nowak,et al.  Only three driver gene mutations are required for the development of lung and colorectal cancers , 2014, Proceedings of the National Academy of Sciences.

[38]  Ellen T. Gelfand,et al.  Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.

[39]  Benjamin Haibe-Kains,et al.  Inconsistency in large pharmacogenomic studies , 2013, Nature.

[40]  Fang Zhang,et al.  Identification of Survival Genes in Human Glioblastoma Cells by Small Interfering RNA Screening , 2009, Molecular Pharmacology.

[41]  A. Gemma,et al.  F1000 highlights , 2010 .

[42]  Sreenath V. Sharma,et al.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.

[43]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[44]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[45]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[46]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[47]  Paz Polak,et al.  Differential relationship of DNA replication timing to different forms of human mutation and variation. , 2012, American journal of human genetics.

[48]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[49]  Crispin J. Miller,et al.  Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. , 2014, Cancer research.

[50]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[51]  T. Triche,et al.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas , 2009, Molecular Cancer Therapeutics.

[52]  F. Shepherd,et al.  Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  A. Bardelli,et al.  Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.

[54]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[56]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[57]  S. Goodman,et al.  RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. , 2008, Cancer research.

[58]  P. Economopoulou,et al.  Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. , 2015, Cancer treatment reviews.

[59]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[60]  L. Milanesi,et al.  Molecular dynamics and docking simulation of a natural variant of Activated Protein C with impaired protease activity: implications for integrin-mediated antiseptic function , 2015, Journal of biomolecular structure & dynamics.

[61]  Ashish Choudhary,et al.  High-throughput RNAi Screening Identifies a Role for TNK1 in Growth and Survival of Pancreatic Cancer Cells , 2011, Molecular Cancer Research.

[62]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[63]  Theresa Zhang,et al.  Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.

[64]  Matthew B. Callaway,et al.  MuSiC: Identifying mutational significance in cancer genomes , 2012, Genome research.

[65]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[67]  Fabrizio Marinelli,et al.  Two-state dynamics of the SH3–SH2 tandem of Abl kinase and the allosteric role of the N-cap , 2013, Proceedings of the National Academy of Sciences.

[68]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[69]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[70]  S. Mousses,et al.  Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. , 2012, Cancer research.

[71]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[72]  Pablo Tamayo,et al.  Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.

[73]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[74]  G. C,et al.  Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors , 2014, Scientific Reports.

[75]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[76]  Saijuan Chen,et al.  A panoramic view of acute myeloid leukemia , 2013, Nature Genetics.

[77]  J. Rigas,et al.  Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[78]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[79]  David Tamborero,et al.  OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..

[80]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[81]  Tingjun Hou,et al.  P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape , 2014, PLoS Comput. Biol..

[82]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.